MedTrace Logo

Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

NCT00966940 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2012-06-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety and efficacy of Travoprost 0.004% and Tafluprost 0.0015% in patients with primary open angle glaucoma or ocular hypertension when both medications are administered in the evening.

Conditions

Interventions

DRUG

Travoprost 0.004% ophthalmic solution (TRAVATAN)

One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration

DRUG

Tafluprost 0.0015% ophthalmic solution

One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-03-31
Completion
2010-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00966940 on ClinicalTrials.gov